Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.51 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3892051 | 0.91 | PLK1 (0.43) | FGFR1PLK1ACLYDHODHCDC7 | |
| SCHEMBL4972881 | 0.88 | FGFR1 (0.52) | FGFR1PLK1CDC7DBF4ALDH1A1 | |
| SCHEMBL3891521 | 0.87 | FGFR1 (0.51) | FGFR1DHODHCDC7DBF4ALDH1A1 | |
| SCHEMBL3890194 | 0.86 | CDC7 (0.45) | FGFR1PLK1CDC7DBF4ALDH1A1 | |
| SCHEMBL4971293 | 0.85 | FGFR1 (0.55) | FGFR1PLK1ALDH1A1HPGDHTT | |
| SCHEMBL3889705 | 0.84 | FGFR1 (0.51) | FGFR1PLK1CDC7DBF4ALDH1A1 | |
| SCHEMBL3893378 | 0.84 | SMN1; SMN2 (0.41) | FGFR1PLK1DHODHCDC7DBF4 | |
| SCHEMBL3903469 | 0.84 | SMN1; SMN2 (0.41) | FGFR1PLK1DHODHCDC7DBF4 | |
| SCHEMBL3889672 | 0.84 | CDC7 (0.38) | FGFR1PLK1CDC7DBF4ALDH1A1 | |
| SCHEMBL3897336 | 0.84 | CDC7 (0.38) | FGFR1PLK1CDC7DBF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991543-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2008-11-19 | — | — | EP | claimed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | claimed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | claimed |
| CN-101415704-A | 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | CN | disclosed |
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1991543-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203210-A1 | Thiazolyl-benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | FGFR1 609/4885PLK1 2782/4885ACLY 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.